Claims for Patent: 9,580,508

Summary for Patent: 9,580,508

Title:	Bispecific EGFR/c-Met antibodies
Abstract:	Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
Inventor(s):	Chiu; Mark (Spring House, PA), Moores; Sheri (Spring House, PA), Neijssen; Joost (Ultrecht, NL), Parren; Paul (Ultrecht, NL), Schuurman; Janine (Ultrecht, NL)
Assignee:	Janssen Biotech, Inc. (Horsham, PA)
Application Number:	14/283,257
Patent Claims:	1. A method of treating a subject having EGFR and/or C-Met expressing cancer, comprising administering a therapeutically effective amount of an isolated bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody comprising a first heavy chain (HC1), a first light chain (LC1), a second heavy chain (HC2) and a second light chain (LC2), wherein the HC1, the LC1, the HC2 and the LC2 comprise the amino acid sequences of SEQ ID NOs: 199, 200, 201 and 202, respectively, to a patient in need thereof for a time sufficient to treat the cancer. 2. The method of claim 1, wherein the cancer is associated with an EGFR activating mutation, an EGFR gene amplification, increased levels of circulating HGF, a c-Met activating mutation, a c-Met gene amplification or a mutant KRAS. 3. The method of claim 2, wherein the EGFR activating mutation is G719A, G719X (X being any amino acid), L861X (X being any amino acid), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P or T790M substitution, deletion of E746-A750, deletion of R748-P753, insertion of Ala (A) between M766 and A767, insertion of Ser, Val and Ala (SVA) between S768 and V769, and insertion of Asn and Ser (NS) between P772 and H773. 4. The method of claim 3, wherein the EGFR activating mutation is L858R, del(E476, A750) and/or T790M substitution. 5. The method of claim 2, wherein the mutant KRAS has a G12V or G12C substitution. 6. The method of claim 5, wherein the mutant KRAS has a G12V substitution. 7. The method of claim 2, wherein the subject is resistant or has acquired resistance to treatment with erlotinib, gefitinib, afatinib, CO-1686, AZD9192 or cetuximab. 8. The method of claim 2, wherein the cancer is an epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, small cell lung cancer, colorectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharynx cancer, cancer of the nose, pancreatic cancer, skin cancer, oral cancer, cancer of the tongue, esophageal cancer, vaginal cancer, cervical cancer, cancer of the spleen, testicular cancer, gastric cancer, cancer of the thymus, colon cancer, thyroid cancer, liver cancer, hepatocellular carcinoma (HCC) or sporadic or hereditary papillary renal cell carcinoma (PRCC). 9. The method of claim 8, wherein the subject is homozygous for phenylalanine at position 158 of CD16 or heterozygous for valine and phenylalanine at position 158 of CD16. 10. The method of claim 8, comprising administering a second therapeutic agent, wherein the second therapeutic agent is a chemotherapeutic agent or a targeted anti-cancer therapy. 11. The method of claim 10, wherein the chemotherapeutic agent is cisplatin or vinblastine. 12. The method of claim 10, wherein the chemotherapeutic agent or the targeted anti-cancer therapy is a tyrosine kinase inhibitor of EGFR, c-Met, HER2, HER3, HER4 or VEGFR. 13. The method of claim 12, wherein the tyrosine kinase inhibitor is erlotinib, gefitinib or afatinib. 14. The method of claim 10, wherein the second therapeutic agent is administered simultaneously, sequentially or separately. 15. A method of inhibiting growth or proliferation of cells that express EGFR and/or c-Met, comprising contacting the cells with the bispecific EGFR/c-Met antibody comprising the HC1, the LC1, the HC2 and the LC2 of SEQ ID NOs: 199, 200, 201 and 202, respectively. 16. A method of inhibiting growth or metastasis of EGFR and/or c-Met expressing tumor or cancer cells in a subject comprising administering to the subject an effective amount of the bispecific EGFR/c-Met antibody comprising the HC1, the LC1, the HC2 and the LC2 of SEQ ID NOs: 199, 200, 201 and 202, respectively, to inhibit the growth or metastasis of EGFR and/or c-Met expressing tumor or cancer cells. 17. The method of claim 16, wherein the EGFR and/or c-Met expressing tumor is an epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, small cell lung cancer, colorectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharynx cancer, cancer of the nose, pancreatic cancer, skin cancer, oral cancer, cancer of the tongue, esophageal cancer, vaginal cancer, cervical cancer, cancer of the spleen, testicular cancer, gastric cancer, cancer of the thymus, colon cancer, thyroid cancer, liver cancer, hepatocellular carcinoma (HCC) or sporadic or hereditary papillary renal cell carcinoma (PRCC). 18. The method of claim 17, wherein the EGFR and/or c-Met expressing tumor is associated with an EGFR activating mutation, an EGFR gene amplification, increased levels of circulating HGF, a c-Met activating mutation, a c-Met gene amplification or a mutant KRAS. 19. The method of claim 18, wherein the EGFR activating mutation is G719A, G719X (X being any amino acid), L861X (X being any amino acid), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P or T790M substitution, deletion of E746-A750, deletion of R748-P753, insertion of Ala (A) between M766 and A767, insertion of Ser, Val and Ala (SVA) between S768 and V769, and insertion of Asn and Ser (NS) between P772 and H773. 20. The method of claim 19, wherein the EGFR activating mutation is L858R, del(E476, A750) and/or T790M substitution. 21. The method of claim 18, wherein the mutant KRAS has a G12V or G12C substitution. 22. The method of claim 21, wherein the mutant KRAS has a G12V substitution.

Details for Patent 9,580,508

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	9,580,508	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007	9,580,508	2039-02-26
Janssen Biotech, Inc.	RYBREVANT	amivantamab-vmjw	Injection	761210	May 21, 2021	9,580,508	2039-02-26